Developer docs
API playgroundTry for free, no card

Search company profiles

Accent Therapeutics

Full company profile

uuid0000b11

Namestring
Accent Therapeutics
Legal namestring
ACCENT THERAPEUTICS
Websiteurl
accenttx.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, small molecule drug discovery, cancer genomic instability, clinical-stage biopharmaceutical, targeted cancer therapy
Industry4 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Precision Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharma company developing small molecule cancer therapeutics. Revenue expected from future drug commercialization upon regulatory approval. The company retains full worldwide rights to its KIF18A program and DHX9 program.

accenttx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Accent Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision oncology drugs that exploit genomic and chromosomal instability in cancer cells. Its lead program ATX-295 is an oral KIF18A inhibitor in Phase 1/2 clinical trials for platinum-resistant ovarian cancer and squamous non-small cell lung cancer, with a partnership with AstraZeneca covering RNA-modifying protein targets and a preclinical program licensed to Boehringer Ingelheim.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 60-70% of ovarian cancer patients will eventually develop platinum resistance
+1 more record
Product overview1 text field

Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering small molecule precision cancer therapies. The company's portfolio includes ATX-295, a potentially best-in-class KIF18A inhibitor currently in Phase 1/2 clinical trials for ovarian and lung cancers, and a licensed preclinical oncology program targeting ISG expression acquired by Boehringer Ingelheim. The company leverages expertise in genomic instability and RNA-modifying proteins to develop targeted cancer therapies.

Product and service3 records
1ATX-295
CategoryClinical-stage drug candidate
Description

A potentially best-in-class oral small molecule inhibitor of KIF18A, a mitotic kinesin motor protein critical for cell division in tumors with chromosomal instability. ATX-295 induces rapid cell death in aneuploid cancer cells while leaving euploid (normal) cells unaffected, and is currently in Phase 1/2 clinical trials for high-grade serous ovarian cancer and squamous non-small cell lung cancer. It is being developed for oncology indications with high unmet need where selective tumor cell killing can be achieved.

2ATX-559
CategoryClinical-stage drug candidate (terminated)
Description

A first-in-class oral small molecule inhibitor of DHX9, an RNA and DNA/RNA helicase target active in tumors with high replication stress. ATX-559 was being studied in a Phase 1/2 clinical trial for solid tumors including BRCA1/2-deficient breast cancer and MSI-H/dMMR tumors. The program was terminated due to adverse event profile and Accent is evaluating strategic options.

3Preclinical ISG Expression Program
CategoryLicensed preclinical program
Description

A novel preclinical small molecule oncology program targeting tumors with high interferon-stimulated gene (ISG) expression, designed to stimulate antitumor immunity. The program was licensed to Boehringer Ingelheim, which assumed global responsibility for research, development, manufacturing, and commercialization.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Boehringer Ingelheim has entered into an agreement to acquire from Accent a novel preclinical small molecule program with an approach for tumors characterized by high interferon-stimulated gene (ISG) expression. Boehringer Ingelheim has assumed global responsibility for the program's research, development, manufacturing, and commercialization, advancing it toward clinical evaluation.

biospace.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Accent and AstraZeneca have a transformational partnership to discover, develop and commercialize certain novel therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration seeks to rapidly advance and achieve the rich therapeutic potential of the exciting programs under partnership by combining AstraZeneca's proven track record in bringing forward novel oncology medicines with Accent's industry-leading expertise in the biology, target identification and drug discovery of RMP-targeting therapies.

Strategic tierCoreTypeTechnology or Integration
Description

Accent Therapeutics is using Inocras' CancerVision and MRDVision platforms in a Phase 1/2 clinical study of ATX-295. The platforms provide detailed tumor genomic profiling and ultra-sensitive monitoring of treatment response, supporting drug development and clinical decision-making.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality-based small molecule therapies. Directly comparable to Accent in targeting novel cancer biology vulnerabilities in genomically defined patient populations.

TypeDirect peer
Description

Precision oncology company developing synthetic lethality-based small molecule drugs. Similar clinical stage, similar focus on novel cancer targets and biomarker-driven patient selection strategies.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule targeted therapies across multiple tumor types. Comparable in targeting novel oncogenic drivers and genomically defined patient populations.

TypeDirect peer
Description

Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies. Comparable clinical stage with similar strategy of targeting novel cancer biology with biomarker-driven development.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple small molecule drug candidates. Similar clinical-stage profile, biomarker-driven development approach, and oncology focus.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule drugs targeting chromatin biology in cancer. Comparable in developing small molecule precision oncology therapies targeting novel cancer biology mechanisms.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule allosteric modulators. Comparable in targeting previously undrugged cancer biology with novel small molecule approaches.

TypeEmerging player
Description

Clinical-stage biotech developing small molecule targeted protein degraders with multiple oncology programs. Overlaps with Accent in precision oncology and novel target biology, though focused on degradation rather than inhibition.

TypeBroad incumbent
Description

Global biopharmaceutical company with a major oncology franchise and an existing partnership with Accent on RNA-modifying proteins. Relevant as a broad incumbent in precision oncology and as Accent's strategic partner.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Global biopharmaceutical company with a leading oncology franchise and an investor in Accent Therapeutics. Comparable as a broad incumbent in oncology drug development and a strategic investor relationship.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accent Therapeutics

Precision Oncology Therapeuticsaccenttx.com

Accent Therapeutics firmographics

Firmographics
Name
Accent Therapeutics
Legal name
ACCENT THERAPEUTICS
Website
https://accenttx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Accent Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Small molecule drug discovery
  • Cancer genomic instability
  • Clinical-stage biopharmaceutical
  • Targeted cancer therapy

Where Accent Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Accent Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharma company developing small molecule cancer therapeutics. Revenue expected from future drug commercialization upon regulatory approval. The company retains full worldwide rights to its KIF18A program and DHX9 program.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Accent Therapeutics product offering

Product offering

Core offering

Accent Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision oncology drugs that exploit genomic and chromosomal instability in cancer cells. Its lead program ATX-295 is an oral KIF18A inhibitor in Phase 1/2 clinical trials for platinum-resistant ovarian cancer and squamous non-small cell lung cancer, with a partnership with AstraZeneca covering RNA-modifying protein targets and a preclinical program licensed to Boehringer Ingelheim.

Product overview

Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering small molecule precision cancer therapies. The company's portfolio includes ATX-295, a potentially best-in-class KIF18A inhibitor currently in Phase 1/2 clinical trials for ovarian and lung cancers, and a licensed preclinical oncology program targeting ISG expression acquired by Boehringer Ingelheim. The company leverages expertise in genomic instability and RNA-modifying proteins to develop targeted cancer therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATX-295 A potentially best-in-class oral small molecule inhibitor of KIF18A, a mitotic kinesin motor protein critical for cell division in tumors with chromosomal instability. ATX-295 induces rapid cell death in aneuploid cancer cells while leaving euploid (normal) cells unaffected, and is currently in Phase 1/2 clinical trials for high-grade serous ovarian cancer and squamous non-small cell lung cancer. It is being developed for oncology indications with high unmet need where selective tumor cell killing can be achieved.
  • ATX-559 A first-in-class oral small molecule inhibitor of DHX9, an RNA and DNA/RNA helicase target active in tumors with high replication stress. ATX-559 was being studied in a Phase 1/2 clinical trial for solid tumors including BRCA1/2-deficient breast cancer and MSI-H/dMMR tumors. The program was terminated due to adverse event profile and Accent is evaluating strategic options.
  • Preclinical ISG Expression Program A novel preclinical small molecule oncology program targeting tumors with high interferon-stimulated gene (ISG) expression, designed to stimulate antitumor immunity. The program was licensed to Boehringer Ingelheim, which assumed global responsibility for research, development, manufacturing, and commercialization.

Quantifiable outcome

  • 60-70% of ovarian cancer patients will eventually develop platinum resistance
  • +1 more outcomes

Companies that use Accent Therapeutics

Customer profile

Segments4 records

Ideal customer profiles2 records

Accent Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Accent Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 8 October 2025Boehringer Ingelheim has entered into an agreement to acquire from Accent a novel preclinical small molecule program with an approach for tumors characterized by high interferon-stimulated gene (ISG) expression. Boehringer Ingelheim has assumed global responsibility for the program's research, development, manufacturing, and commercialization, advancing it toward clinical evaluation.
  • AstraZenecaflagshipStrategic or Co-development PartnerAccent and AstraZeneca have a transformational partnership to discover, develop and commercialize certain novel therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration seeks to rapidly advance and achieve the rich therapeutic potential of the exciting programs under partnership by combining AstraZeneca's proven track record in bringing forward novel oncology medicines with Accent's industry-leading expertise in the biology, target identification and drug discovery of RMP-targeting therapies.
  • InocrascoreTechnology or IntegrationAccent Therapeutics is using Inocras' CancerVision and MRDVision platforms in a Phase 1/2 clinical study of ATX-295. The platforms provide detailed tumor genomic profiling and ultra-sensitive monitoring of treatment response, supporting drug development and clinical decision-making.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Accent Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based small molecule therapies. Directly comparable to Accent in targeting novel cancer biology vulnerabilities in genomically defined patient populations.
  • Repare Therapeutics: Precision oncology company developing synthetic lethality-based small molecule drugs. Similar clinical stage, similar focus on novel cancer targets and biomarker-driven patient selection strategies.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing small molecule targeted therapies across multiple tumor types. Comparable in targeting novel oncogenic drivers and genomically defined patient populations.
  • Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies. Comparable clinical stage with similar strategy of targeting novel cancer biology with biomarker-driven development.
  • Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple small molecule drug candidates. Similar clinical-stage profile, biomarker-driven development approach, and oncology focus.
  • Foghorn Therapeutics: Clinical-stage biotech developing small molecule drugs targeting chromatin biology in cancer. Comparable in developing small molecule precision oncology therapies targeting novel cancer biology mechanisms.
  • HotSpot Therapeutics: Clinical-stage precision oncology company developing small molecule allosteric modulators. Comparable in targeting previously undrugged cancer biology with novel small molecule approaches.

Emerging players

  • Kymera Therapeutics: Clinical-stage biotech developing small molecule targeted protein degraders with multiple oncology programs. Overlaps with Accent in precision oncology and novel target biology, though focused on degradation rather than inhibition.

Broad incumbents

  • AstraZeneca: Global biopharmaceutical company with a major oncology franchise and an existing partnership with Accent on RNA-modifying proteins. Relevant as a broad incumbent in precision oncology and as Accent's strategic partner.
  • Bristol-Myers Squibb: Global biopharmaceutical company with a leading oncology franchise and an investor in Accent Therapeutics. Comparable as a broad incumbent in oncology drug development and a strategic investor relationship.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Accent Therapeutics social profiles

Digital presence

Accent Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accent Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Accent Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accent Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accent Therapeutics

What does Accent Therapeutics do?

Accent Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision oncology drugs that exploit genomic and chromosomal instability in cancer cells. Its lead program ATX-295 is an oral KIF18A inhibitor in Phase 1/2 clinical trials for platinum-resistant ovarian cancer and squamous non-small cell lung cancer, with a partnership with AstraZeneca covering RNA-modifying protein targets and a preclinical program licensed to Boehringer Ingelheim.

Is Accent Therapeutics a public or private company?

Accent Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Accent Therapeutics founded?

Accent Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Accent Therapeutics based?

Accent Therapeutics is headquartered in Lexington, United States, in the North America region.

How does Accent Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Accent Therapeutics's main competitors?

Direct peers on record are Tango Therapeutics, Repare Therapeutics, Black Diamond Therapeutics, Relay Therapeutics, Erasca, Foghorn Therapeutics and HotSpot Therapeutics. Kymera Therapeutics is listed as an emerging player. Broad incumbents are AstraZeneca and Bristol-Myers Squibb.

Does Accent Therapeutics have an API?

No public API is recorded for Accent Therapeutics.

What industry is Accent Therapeutics in?

Accent Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cancer NetworkDeveloper Terminates DHX9 Inhibitor Trial Amid Safety ConcernsAccent Therapeutics has terminated the development of its lead candidate ATX-559, an oral DHX9 inhibitor, due to safety concerns and adverse events observed in a phase 1/2 clinical trial for metastatic solid tumors. The company is currently pivoting its focus to advance its alternative lead candidate, ATX-295, which is being evaluated for platinum-resistant ovarian cancer.PR NewswireAccent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual MeetingAccent Therapeutics announced it will present a Trial in Progress poster at the 2026 ASCO Annual Meeting describing its ongoing Phase 1/2 first-in-human clinical study of ATX-295, a potentially best-in-class oral KIF18A inhibitor for patients with advanced or metastatic solid tumors including high-grade serous ovarian cancer and squamous non-small cell lung cancer. The study, currently open and actively enrolling, comprises a dose-escalation phase to determine the recommended Phase 2 dose followed by a dose-expansion phase assessing preliminary antitumor activity, with primary endpoints focused on safety, tolerability, and dose determination.PR NewswireAccent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual MeetingAccent Therapeutics presented preclinical data at the 2026 AACR Annual Meeting for its KIF18A inhibitor ATX-295, demonstrating robust and durable anti-tumor activity across multiple solid tumor models with high chromosomal instability, including high-grade serous ovarian cancer, squamous non-small cell lung cancer, and triple-negative breast cancer. The drug candidate also showed proof-of-concept for an AI-based biomarker capable of detecting whole-genome doubling in clinical samples. ATX-295 is currently under evaluation in a Phase 1/2 first-in-human study for patients with locally advanced or metastatic solid tumors.PR NewswireAccent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual MeetingAccent Therapeutics announced it will present preclinical data on its KIF18A inhibitor ATX-295 at the 2026 AACR Annual Meeting in San Diego, demonstrating anti-tumor activity in high-grade serous ovarian, squamous non-small cell lung, and triple-negative breast cancer models. The drug targets cancer vulnerabilities derived from genomic and chromosomal instability, causing rapid cell death in aneuploid cancer cells while sparing healthy euploid cells. ATX-295 is currently being evaluated in a Phase 1/2 clinical study enrolling patients with locally advanced or metastatic solid tumors.FierceBiotechAccent halts solid tumor trial over adverse events, pivots to other lead cancer programAccent Therapeutics has terminated its phase 1/2 study of ATX-559, an oral DHX9 inhibitor for solid tumors including BRCA1/2-deficient breast cancer and MSI-H/dMMR tumors, citing an adverse event profile that prompted the company to evaluate strategic options for the program. The Cambridge, Massachusetts-based biotech is now redirecting resources to its other lead candidate, ATX-295, a KIF18A inhibitor currently in a phase 1/2 trial for platinum-resistant ovarian cancer that the company plans to expand to additional cancer types. The company confirmed the program shift has not resulted in any layoffs, while noting it has partnered with AstraZeneca on RNA-modifying proteins for cancer treatment and licensed a preclinical molecule to Boehringer Ingelheim.GenengnewsSLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable TumorsAt the SLAS 2025 conference in Boston, Accent Therapeutics chief scientific officer Dr. Serena Silver delivered the opening keynote on KIF18A, a motor protein that is selectively required for cell division in chromosomally unstable cancer cells but not in normal cells. The company has developed ATX-295, a highly selective KIF18A inhibitor derived from an Amgen-discovered molecule that demonstrated dose-dependent tumor regression in chromosomally unstable models while leaving stable cancer cells unaffected, and has advanced into a Phase I/II clinical trial for platinum-resistant ovarian cancer. Accent used the Broad Institute's PRISM platform to screen 45 tumor types, identifying head and neck, lung, and breast cancers with high genomic instability as additional potential indications, and is leveraging Imagene's AI image analysis to identify chromosomal instability in tumor tissue.BioSpaceAccent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical StudyInocras announced that Accent Therapeutics will deploy its CancerVision and MRDVision whole genome platforms in the first-in-human Phase 1/2 dose-escalation study of ATX-295, a KIF18A protein inhibitor being developed for cancer treatment. CancerVision provides tumor genomic profiling while MRDVision enables ultra-sensitive monitoring of treatment response during dose escalation. The collaboration underscores the use of whole genome profiling as a critical tool in next-generation drug development.PR NewswireAccent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsAccent Therapeutics presented new preclinical data on its two lead oncology programs at the AACR-NCI-EORTC International Conference, with ATX-295 demonstrating enriched activity in ovarian and triple-negative breast cancer models with whole genome doubling, and ATX-559 showing potent activity in MSI-H and BRCA-deficient cancer models. Both programs are currently being evaluated in Phase 1/2 clinical trials. The data highlight the company's biomarker-driven strategy targeting genomic instability in cancer cells for selective tumor cell death.BioSpaceAccent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsAccent Therapeutics presented new preclinical data on its two lead oncology programs at the 2025 AACR-NCI-EORTC International Conference in Boston. The KIF18A inhibitor ATX-295 demonstrated enriched activity in ovarian and triple-negative breast cancer models with whole genome doubling, while the first-in-class DHX9 inhibitor ATX-559 showed potent activity in MSI-H and BRCA-deficient cancers, with both programs inducing dose-dependent tumor regression in preclinical models. Both candidates are currently being evaluated in Phase 1/2 clinical trials.